Hyundai Bioscience said Sunday that it will co-develop a broad-spectrum antiviral drug with the US National Institutes of Health, a federal agency for conducting and supporting medical research and the world’s largest public funder of biomedical research. A non-clinical evaluation agreement was signed on Friday between Hyundai Bioscience USA, a US-based subsidiary of the Korean pharmaceutical company, and the N.
Hyundai Bioscience said Sunday it will develop a broad-spectrum antiviral drug with the U.S. National Institutes of Health (NIH), a federal agency for conducting and supporting medical research.
Hyundai Bioscience, U.S. NIH to Co-develop Broad-spectrum Antiviral Drug koreabizwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreabizwire.com Daily Mail and Mail on Sunday newspapers.